ImaginAb, Inc.

Industry

  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • In Vitro Diagnostics
    • Saliva-based Testing
See more in Biomedtracker

Latest on ImaginAb, Inc.

Scrip

Asia Deal Watch: Regenxbio Licenses Two MPS Gene Therapies To Nippon Shinyaku

 
• By Joseph Haas, Lisa Takagi, and Dexter Jie Yan

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regenxbio Calls On Nippon Shinyaku To

Scrip

Finance Watch: Theravance Eliminates Debt In $1.1bn Trelegy Royalty Sell-Off

 
• By Mandy Jackson

Theravance Biopharma Inc. will eliminate debt from its balance sheet and improve its cash balance through the sale of its interest in Theravance Respiratory Company LLC (TRC) – representing an 85% sh

Scrip

Asia Deal Watch: Astellas, GO Team Up On Targeted Cancer Therapy

 
• By Joseph Haas, Jung Won Shin, Dexter Jie Yan, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Astellas/Xyphos And GO Target Glycoprot

Scrip

Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal

 
• By Joseph Haas, Vibha Ravi, and Mandy Jackson

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Seagen, RemeGen Partner Outside Asia, E